https://mindmedicinelaw.com/briefing/psychedelic-use-motives-in-us-young-adults-insights-implications-20260619-14626The Psychedelic Journalen2026-06-20T15:04:09.032821+00:00Psychedelic Use Motives in US Young Adults: Insights & Implicationspsychedelic use, young adults, microdosing, public health, regulatory frameworks, information sources, mental health, social media, harm reduction, policy implicationshttps://mindmedicinelaw.com/briefing/media-impact-on-psychedelic-research-and-policy-a-2026-analysis-20260618-14527The Psychedelic Journalen2026-06-20T15:04:18.711951+00:00Media Impact on Psychedelic Research and Policy: A 2026 Analysismedia influence, psychedelic therapies, MDMA, FDA decision, public perception, scientific evidence, policy development, research communication, cyclical media trendshttps://mindmedicinelaw.com/briefing/mdma-study-with-psychoanalytic-psychotherapists-new-insights-20260618-14548The Psychedelic Journalen2026-06-19T22:06:54.750143+00:00MDMA Study with Psychoanalytic Psychotherapists: New InsightsMDMA-assisted psychotherapy, psychoanalytic psychotherapists, psychological mechanisms, qualitative study, psychedelic therapy, PTSD treatmenthttps://mindmedicinelaw.com/briefing/psilocin-distribution-in-zebrafish-implications-for-safety-20260618-14547The Psychedelic Journalen2026-06-19T22:06:44.458274+00:00Psilocin Distribution in Zebrafish: Implications for Safetypsilocin distribution, zebrafish model, DESI-MSI, neurobehavioral effects, psychedelic safety, psilocybin research, drug distribution mapping, clinical implications, psychedelic policy, toxicology studieshttps://mindmedicinelaw.com/briefing/lsd-s-impact-on-motor-learning-and-stress-new-clinical-insights-20260618-14528The Psychedelic Journalen2026-06-19T22:06:24.034801+00:00LSD's Impact on Motor Learning and Stress: New Clinical InsightsLSD, motor learning, stress reduction, neuroplasticity, psychedelic research, clinical trials, cognitive flexibility, neurophysiological effects, long-term potentiation, therapeutic applicationshttps://mindmedicinelaw.com/briefing/psychedelic-healing-initiative-for-system-impacted-individuals-20260618-14320The Psychedelic Journalen2026-06-18T22:04:06.073895+00:00Psychedelic Healing Initiative for System-Impacted Individualspsychedelic-assisted healing, system-impacted individuals, marginalized communities, policy reform, public health, clinical trials, psilocybin, MDMA, equity in research, therapeutic potentialhttps://mindmedicinelaw.com/briefing/parkinson-s-disease-models-chemical-vs-genetic-approaches-20260617-14585The Psychedelic Journalen2026-06-20T15:04:28.601597+00:00Parkinson's Disease Models: Chemical vs. Genetic Approachesparkinson's disease, chemical models, genetic models, hybrid models, neurodegeneration, clinical trials, neuroscience, disease-modifying therapies, AI-assisted research, translational gaphttps://mindmedicinelaw.com/briefing/mental-health-professionals-views-on-psychedelics-for-sud-20260617-14529The Psychedelic Journalen2026-06-19T22:07:10.766524+00:00Mental Health Professionals' Views on Psychedelics for SUDpsychedelic-assisted therapy, substance use disorders, mental healthcare professionals, education and training, clinical integration, safety concernshttps://mindmedicinelaw.com/briefing/schizophrenia-gene-ensemble-and-decision-noise-new-insights-20260617-14562The Psychedelic Journalen2026-06-19T22:07:03.373726+00:00Schizophrenia Gene Ensemble and Decision Noise: New Insightsschizophrenia, prefrontal neuron ensemble, decision noise, pharmacological strategy, NMDA receptor, clozapine, multi-receptor antagonist, precision medicine, mental health treatment, psychiatric disordershttps://mindmedicinelaw.com/briefing/ibogaine-mortality-risk-new-study-analyzes-19-071-patients-20260617-14559The Psychedelic Journalen2026-06-19T22:06:34.170589+00:00Ibogaine Mortality Risk: New Study Analyzes 19,071 Patientsibogaine, mortality risk, psychedelic treatment, clinical protocols, safety standards, regulatory perspectives, addiction treatment, psychoactive substances, neuroscience, public healthhttps://mindmedicinelaw.com/briefing/psychedelics-ketamine-psychiatry-s-new-frontier-in-poland-20260615-14567The Psychedelic Journalen2026-06-20T15:03:35.781019+00:00Psychedelics & Ketamine: Psychiatry's New Frontier in Polandpsychedelics, ketamine, psychiatry, neuroplasticity, Poland, mental health, 5-HT2A receptor, clinical trials, ethical frameworks, healthcare integrationhttps://mindmedicinelaw.com/briefing/trait-nem-s-role-in-mdma-response-insights-and-implications-20260606-14555The Psychedelic Journalen2026-06-20T15:03:58.731994+00:00Trait NEM's Role in MDMA Response: Insights and Implicationsnegative emotionality, MDMA response, oxytocin release, social connectedness, clinical trials, psychedelic therapy, individual differences, sex differences, neurobiology, psychiatric conditionshttps://mindmedicinelaw.com/briefing/nem-s-impact-on-mdma-therapy-insights-for-clinicians-20260606-14554The Psychedelic Journalen2026-06-20T15:03:47.151495+00:00NEM's Impact on MDMA Therapy: Insights for Cliniciansnegative emotionality, MDMA response, personality traits, clinical trials, oxytocin release, sex differences, psychedelic therapy, patient selection, dose optimization, treatment heterogeneity